Ist GIPC ein neuer Kandidat für die Therapie des Pankreaskarzinoms?

Translated title of the contribution: GIPC: a new target for therapy in pancreatic adenocarcinoma?

M. H. Muders, G. B. Baretton, D. E. Aust, S. K. Dutta, E. Wang, Y. Ikeda, M. R. Spaller, K. Datta, D. Mukhopadhyay

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

GIPC is highly expressed in human pancreatic adenocarcinoma and is a central protein for the stability of IGF-1R in pancreatic adenocarcinoma cell lines (15). The goal of this study was to prove the importance of GIPC in vivo and to evaluate possible therapeutic strategies that target this protein and its PDZ domain. In vivo effects of GIPC knockout were studied after lentiviral transduction of luciferase-expressing MiaPaCa2 pancreatic cancer cells with shRNA against GIPC; growth characteristics were monitored with bioluminiscence. Knockdown of GIPC led to a significant inhibition of pancreatic tumor cell growth in vivo in different mouse models. To test a possible therapeutic approach, the PDZ domain of GIPC was targeted by a short peptide composed of the amino acid sequence PSQSSSEA. This octapeptide was designed based on the C-terminal binding motif of GAIP. Targeting GIPC with this peptide inhibited the association between IGF-1R and GIPC. The subsequent downregulation of IGF-1R decreased proliferation in vitro and in vivo. In conclusion, our findings suggest that targeting GIPC and its PDZ domain-mediated interaction with the tyrosine kinase receptor IGF-1R could be a promising new treatment option for pancreatic cancer.

Translated title of the contributionGIPC: a new target for therapy in pancreatic adenocarcinoma?
Original languageGerman
Pages (from-to)286-293
Number of pages8
JournalVerhandlungen der Deutschen Gesellschaft für Pathologie
Volume91
StatePublished - 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'GIPC: a new target for therapy in pancreatic adenocarcinoma?'. Together they form a unique fingerprint.

  • Cite this

    Muders, M. H., Baretton, G. B., Aust, D. E., Dutta, S. K., Wang, E., Ikeda, Y., Spaller, M. R., Datta, K., & Mukhopadhyay, D. (2007). Ist GIPC ein neuer Kandidat für die Therapie des Pankreaskarzinoms? Verhandlungen der Deutschen Gesellschaft für Pathologie, 91, 286-293.